Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALZ-507
- Development stage
- Phase 1
- Lead developer
- Alzheon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALZ-507 is an orally administered small molecule drug being developed by Alzheon for the treatment of Alzheimer's disease. It is designed as a next-generation follow-on to Alzheon's lead candidate, valiltramiprosate (ALZ-801). ALZ-507 targets upstream amyloid aggregation to inhibit the formation of neurotoxic soluble amyloid oligomers, which are considered key drivers of Alzheimer's pathology. Additionally, the drug incorporates an APOE4 corrector mechanism of action, potentially enhancing its anti-oligomer effects. Developed for once-daily oral administration, ALZ-507 aims to provide improved gastrointestinal tolerability and a favorable safety profile. It is currently in Phase 1 clinical development.
02
Targets
APOE4 (Apolipoprotein E4)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on ALZ-507.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALZ-507.